17 December 2019

The Dutch Kidney Foundation supports talented postdocs and physician researchers through providing personal grants that support different phases of a research career. Kolff grant recipients are foreseen to make important contributions to the field of renal research and to stimulate the application of research results in practice.

The Kolff grants recipients are: Project title: Innate immune-regulating nanotherapy for renal transplantation

Patients undergoing kidney transplantation are treated with immunosuppressive medication mainly aimed at suppression of the adaptive immune system. These drugs are effective but come at the cost of substantial adverse side effects, such as infections, cancer, and diabetes. In his research he focuses on the development of a new type of treatment aimed at the innate immune system with the aim of preventing acute rejection. For this purpose he will use nanotechnology to deliver medication very specifically to monocytes and macrophages. This has the advantage of efficient delivery of drugs specifically to these cells, while the total amount of medication that enters the body can be minimized, reducing potential side effects. Project title: PRednisOne effectS on Podocytes; rEsolving the moleculaR enigma - The PROSPER study.

Nephrotic syndrome (NS) is characterized by massive proteinuria, hypoalbuminemia and edema, as a result of extensive podocyte foot process effacement. The mainstay of therapy for NS patients is prednisone. NS management is as yet unpredictable, mainly because the molecular mechanisms underlying NS and prednisone treatment are poorly understood. Moreover, prednisone treatment is associated with severe adverse effects. Hence, there is an urgent need to develop more specific therapies to treat NS with less side effects. The aim of her study is to resolve molecular targets regulated by prednisone that are essential for successful podocyte recovery. These results will be instrumental for the development of more specific therapeutic entities to treat NS with less side effects.
 

Related news items


650,000 Euro funding for research into the phasing out of medication for leukaemia patients

30 July 2020

With a 650,000 euro funding from ZonMw, researchers from the Haematology and Pharmacy departments can develop a medication phasing out strategy for patients with chronic myeloid leukaemia. This strategy will be tested in practice.

read more

Increased role of patients after bowel cancer treatment

30 July 2020

Approximately 14,000 patients get colorectal cancer every year. Almost all patients are operated on and monitored afterwards (follow-up). In 2019 Radboudumc started a new approach to follow-up research after the treatment of stage II/III colorectal cancer.

read more

ERC Proof of Concept grant received by Ronald van Rij

30 July 2020

Ronald van Rij, theme Infectious diseases and global health, received an ERC (European Research Council) Proof of Concept grant of 150,000 euros, in order to make arbovirus vaccines even safer.

read more

Hypatia fellowship Call is open

30 July 2020

The Hypatia fellowship round with the deadline 31 May has been canceled. Therefore, the next available deadline will be 27 September 2020. Radboudumc researchers are invited to scout young potentials to fill the strategic gaps within the research themes imbedded in RIHS and RIMLS.  

read more

Mihai Netea and colleagues published two papers back-to-back in The Journal of Clinical Investigation. 

29 July 2020

These back-to-back articles investigated the effect of BCG vaccination on trained immunity. The first article shows that BCG vaccination inhibits systemic inflammation, depending on gender. The second article demonstrates that the circadian rhythm influences the induction of trained immunity.

read more

Genetic mutation reveals how coronavirus strikes TLR7 plays essential role in disease process

28 July 2020

''Does a congenital immune defect play an important role in the defense against Coronavirus?'' This was published by Cas van der Made, Frank van der Veerdonk and Alexander Hoischen.

read more